Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
The picture of chronic liver diseases (CLDs) has changed considerably in recent years. One of them is the increase of non-alcoholic fatty liver disease. More and more CLD patients, even those with liver cirrhosis (LC), tend to be presenting with obesity these days. The annual rate of muscle loss increases with worsening liver reserve, and thus LC patients are more likely to complicate with sarcopenia. LC is also characterized by protein-energy malnutrition (PEM). Since the PEM in LC can be invariable, the patients probably present with sarcopenic obesity (Sa-O), which involves both sarcopenia and obesity. Currently, there is no mention of Sa-O in the guidelines; however, the rapidly increasing prevalence and poorer clinical consequences of Sa-O are recognized as an important public health problem, and the diagnostic value of Sa-O is expected to increase in the future. Sa-O involves a complex interplay of physiological mechanisms, including increased inflammatory cytokines, oxidative stress, insulin resistance, hormonal disorders, and decline of physical activity. The pathogenesis of Sa-O in LC is diverse, with a lot of perturbations in the muscle–liver–adipose tissue axis. Here, we overview the current knowledge of Sa-O, especially focusing on LC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there are no internationally standardized criteria for diagnosing SO [22].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [22]
In the citing paper
“As mentioned earlier, physical inactivity and obesity increase the level of lipid circulation and myosteatosis in skeletal muscle, contributing to a decrease in muscle mass and strength and favoring sarcopenia and physical disabilities [14, 22, 66].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“In LC patients with Sa-O, caution should be exercised for the risk of progression of sarcopenia with weight loss, and patients who are advised to lose weight should be monitored for changes in body composition and muscle strength or physical activities, using appropriate assessment tools [88].”
MethodAsian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 2×
“Primary sarcopenia is defined as a condition in which SMM and muscle strength or physical function decline with aging, while secondary sarcopenia is defined as a condition in which SMM and muscle strength or physical function are impaired due to underlying diseases [3,4].”
BackgroundSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803 · cited 2×
“Primary sarcopenia is defined as a condition in which SMM and muscle strength or physical function decline with aging, while secondary sarcopenia is defined as a condition in which SMM and muscle strength or physical function are impaired due to underlying diseases [3,4].”
BackgroundInflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“In contrast, increase of a visceral fat induces inflammation, contributing to the sarcopenia incidence [49].”
BackgroundAlterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention
Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., Shi, J., Zhao, S., Liu, W., Wang, X., et al. (2017) · Nature Medicine · doi:10.1038/nm.4358 · Cited by 1,501
Long-term health benefits of physical activity – a systematic review of longitudinal studies
Reiner, M., Niermann, C., Jekauc, D., & Woll, A. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-813 · Cited by 1,447
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 1×
“LC patients are likely to be involved in insulin resistance and chronic inflammation [38].”
BackgroundRosenberg, I. H. (1989) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/50.5.1231 · Cited by 1,102
Cited by
Pathophysiology and mechanisms of primary sarcopenia (Review)
Nishikawa, H., Fukunishi, S., Asai, A., Yokohama, K., Nishiguchi, S., & Higuchi, K. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4989 · Cited by 234
Self-citationCancer Cachexia: Its Mechanism and Clinical Significance
Nishikawa, H., Goto, M., Fukunishi, S., Asai, A., Nishiguchi, S., & Higuchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168491 · Cited by 233
“There are several reasons why it is difficult to develop diagnostic criteria for cachexia: (1) due to the effects of ascites and other factors, it is not easy to accurately assess the loss of skeletal muscle mass, which is the main cause of cachexia (in particular, the bioelectrical impedance analysis (BIA) method of…”
MethodSelf-citationThe critical role of oxidative stress in sarcopenic obesity
Gonzalez, A., Simon, F., Achiardi, O., Vilos, C., Cabrera, D., & Cabello-Verrugio, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4493817 · Cited by 79
“As mentioned earlier, physical inactivity and obesity increase the level of lipid circulation and myosteatosis in skeletal muscle, contributing to a decrease in muscle mass and strength and favoring sarcopenia and physical disabilities [14, 22, 66].”
BackgroundAzevedo, V. Z., Silaghi, C. A., Maurel, T., Silaghi, H., Ratziu, V., & Pais, R. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.774030 · Cited by 68
Chang, J., Höfer, P., Böhling, N., Lingohr, P., Manekeller, S., Kalff, J. C., Dohmen, J., Kaczmarek, D. J., Jansen, C., Meyer, C. H., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100442 · Cited by 49
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis
Mallet, M., Silaghi, C. A., Sultanik, P., Conti, F., Rudler, M., Ratziu, V., Thabut, D., & Pais, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000456 · Cited by 34
Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease
Chun, H. S., Lee, M., Lee, H. A., Lee, S., Kim, S.-Y., Jung, Y. J., Lee, C., Kim, H., Lee, H. A., Kim, H. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.11.031 · Cited by 33
Clinical Overview of Sarcopenia, Frailty, and Malnutrition in Patients With Liver Cirrhosis
Kusnik, A. T., Penmetsa, A., Chaudhary, F., Renjith, K., Ramaraju, G. A., Laryea, M. A., & Allard, J. P. (2024) · Gastroenterology Research · doi:10.14740/gr1707 · Cited by 28
Hénin, G., Lanthier, N., & Dahlqvist, G. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.4.10899 · Cited by 29
New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
Alhumaid, S., Mutair, A. S. A., Rabaan, A. A., ALShakhs, F. M., Choudhary, O. P., Yong, S. J., Nainu, F., Khan, A., Muhammad, J., Alhelal, F., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02507-3 · Cited by 26
Lafci, B., Hadjihambi, A., Determann, M., Konstantinou, C., Freijo, C., Herraiz, J. L., Bluemel, S., Pellerin, L., Burton, N. C., Deán‐Ben, X. L., et al. (2023) · Theranostics · doi:10.7150/thno.78548 · Cited by 25
Liver and obesity: a narrative review
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001334 · Cited by 23
Santangeli, E., Abbati, C., Chen, R., di Carlo, A., Leoni, S., Piscaglia, F., & Ferri, S. (2024) · Nutrients · doi:10.3390/nu16030427 · Cited by 24
Elsabaawy, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01493-y · Cited by 21
Xu, X., Tian, M., Ding, C. C., Xu, H., Wang, H., & Jin, X. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae094 · Cited by 19
Danielsson, O., Nissinen, M. J., Jula, A., Salomaa, V. V., Männistö, S., Lundqvist, A., Perola, M., & Åberg, F. O. (2021) · Liver International · doi:10.1111/liv.15053 · Cited by 19
Sarcopenic obesity in liver disease: Handling both sides of the penny
Hui, Y., Cui, B., Wang, X., Sun, M., Li, Y., Yang, W., Guo, G., Mao, L., Yu, Z., Fan, X., et al. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.10 · Cited by 19
Faccioli, J., Nardelli, S., Gioia, S., Riggio, O., & Ridola, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102842 · Cited by 19
Tanaka, M., Kaji, K., Nishimura, N., Asada, S., Koizumi, A., Matsuda, T., Yorioka, N., Tsuji, Y., Fujinaga, Y., Sato, S., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119649 · Cited by 14
Nutritional Management of a Liver Transplant Candidate
Mishra, S., & Premkumar, M. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.03.012 · Cited by 13
Romeo, M., Dallio, M., Cipullo, M., Coppola, A., Mazzarella, C., Mammone, S., Iadanza, G., Napolitano, C., Vaia, P., Ventriglia, L., et al. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf001 · Cited by 13
Obesity and Liver Cancer in Japan: A Comprehensive Review
Nishikawa, H., Fukunishi, S., Asai, A., Nishiguchi, S., & Higuchi, K. (2021) · Anticancer Research · doi:10.21873/anticanres.14999 · Cited by 12
Self-citationWhat Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
Ferenc, K., Jarmakiewicz-Czaja, S., & Filip, R. (2023) · Life · doi:10.3390/life14010037 · Cited by 10
Positive impact of obesity on the prognosis of liver cirrhosis
Endo, K., Kakisaka, K., Abe, T., Yusa, K., Nakaya, I., Watanabe, T., Suzuki, A., Yoshida, Y., Oikawa, T., Miyasaka, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16590 · Cited by 9
Radiological Quantification of Sarcopenic Obesity and its Role in Chronic Liver Disease Severity
Çimşit, C., Kurşun, M., Demircioğlu, Ö., Dilber, F., Demirtaş, C. Ö., & Ergenç, İ. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.03.001 · Cited by 9
Du, J., Shu, L., Zhou, Y., & Zhang, L. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i30.10984 · Cited by 9
Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature
Nishikawa, H., Kim, S. K., Yoshio, S., & ASAI, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041661 · Cited by 7
Self-citationDeeb, A. A., Settmacher, U., Fritsch, J., Dondorf, F., Rohland, O., & Rauchfuß, F. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000238 · Cited by 8
Zhao, H., Liu, Y., Su, L., Cui, P., Sai, J., Li, S., Wang, N., & He, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1727270 · Cited by 5
Quinlan, J. I., Dhaliwal, A., Williams, F. R., Allen, S., Breen, L., Greig, C. A., Lord, J. M., Armstrong, M. J., & Elsharkawy, A. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.817152 · Cited by 5
Dang, W., Wu, S., Liu, X., Shen, H., Chen, Y., Zhang, Z., Wang, H., Cai, Z., Li, M., Sun, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13338-8 · Cited by 6
Wilkinson, M., Ferguson, E. J., Bureau, J., Haggerty-Goede, R. A. L., Miller, D. M., Kuriakose, M., Veeneman, J., Lima, P. D. A., McGlory, C., & Dunham‐Snary, K. J. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1639882 · Cited by 3
Landscape and research trends of sarcopenic obesity research: A bibliometric analysis
Tang, H., Lian, R., Li, R., Jiang, J., & Yang, M. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24696 · Cited by 3
Prevalence and risk factors of sarcopenia in patients with cirrhosis – an observational study
Majeed, A. A., Shaikh, H., Rasheed, A., Khalid, R., Arisar, F. A. Q., & Ghias, H. (2023) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.8461 · Cited by 4
Nutrition Therapy in Critically Ill Patients with Liver Disease: A Narrative Review
Hidalgo-Blanco, M. Á., Delgado, J. C. L., & Guerrero, J. A. S. (2023) · Livers · doi:10.3390/livers3030036 · Cited by 3
Hao, N.-B., Zhou, Y., Li, X., Zhang, D., Hu, W.-W., Xie, J., Ma, X., Tian, T., & Li, C. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102459 · Cited by 3
Shaikh, O. S., Yan, P., & Butt, A. A. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100689 · Cited by 2
Chu, R., Xie, Y., Li, W., Du, Y., Ni, T., Tu, X., Xu, B., & Zhao, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1734359 · Cited by 2
Yang, X., Na, K., Yan, C., & Han, Y. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100796 · Cited by 2
Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse
Elsabaawy, M., & Alhaddad, O. (2024) · Gastroenterology Review · doi:10.5114/pg.2024.136361 · Cited by 2
Wang, Z., Li, S., Wang, K., Zhang, M., Wu, J., Liu, D., & Liang, K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066181 · Cited by 2
Catalina-Palomares, D., Botella-Juan, L., Frutos-Galindo, I. D., Yubero-García, P., Fernández‐Somoano, A., Martín, V., & Marcos‐Delgado, A. (2024) · Revista Española de Nutrición Humana y Dietética · doi:10.14306/renhyd.28.1.1966 · Cited by 1
Herscovici, D. M., Cooper, K. M., Colletta, A., Rightmyer, M., Shingina, A., & Feld, L. D. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90202 · Cited by 1
A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis
Yang, Y., Wei, T., Yang, S., Fei, R., Tie, C., Han, R., Ma, D., Jin, Q., Wang, J., Wang, Z., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1719899 · Cited by 1
Yanaral, T. U., & Karaaslan, P. (2021) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2021.7247 · Cited by 1
Current Topic Concerning Non-Obese Non-Alcoholic Fatty Liver Disease (NAFLD)
Bando, H. (2021) · Institutional Repositories DataBase (IRDB)
Iatrogenic liver diseases: a new concept, with practices to be condemnedPreprint
Elsabaawy, M., & Alhaddad, O. (2023) · Research Square · doi:10.21203/rs.3.rs-3045869/v1
武, 云. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371538
Sarcopenia and sarcopenic obesity in patients awaiting liver transplantation
Fang, L., Liu, X., Tian, Z., Jiang, Y., Ding, X., Zhang, L., & Jing, X. (2023) · Portal hypertension & cirrhosis · doi:10.1002/poh2.52
Rehabilitácia Pri Cirhóze Pečene
Sekereš, M. (2023) · časopis REHABILITÁCIA · doi:10.61983/lcrh.v60i3.5 · Cited by 1
SARCOPENIC OBESITY – THE DIAGNOSTIC PARADIGM
Taran, N., Lupaşco, I., Vengher, I., & Ghelimici, T. (2023) · Arta Medica · doi:10.5281/zenodo.10429320
Obesity Assessment in Cirrhosis with Ascites: Challenges and Emerging Solutions
Elsabaawy, M. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00728-8
Sarcopenic obesity in cirrhosis: prognostic value and future perspectives
Chen, Y., Liao, Z., Wang, C., Zhang, Y., & Huang, R. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01154-9
Zhang, W., Yuan, J., Li, Y., Liu, Y., Wang, X., Tuo, S., Shi, M., Wang, J., Dai, S., Li, L., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1817771
Zhao, H.-J., Su, L.-H., Lu, F., Gao, F., Sai, J., Li, P., Shi, J., Wang, L., Li, S.-J., Zhou, F., et al. (2026) · World Journal of Hepatology · doi:10.4254/wjh.122692
Rapid skeletal muscle loss in cirrhosis: the ‘silent killer’ within CT imaging
Armstrong, M. J., & Williams, F. R. (2026) · Gut · doi:10.1136/gutjnl-2026-340144
Zhao, D., Fan, Z., Yan, Y., Qiaoli, G., Xu, Q., Hao, Z., & Huang, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1911832
Metadata
- Authors
- Nishikawa, H., Enomoto, H., Nishiguchi, S., & Iijima, H.
- Affiliations
- Hyogo Medical University (JP)
- KANO General Hospital (JP)
- Corresponding author
- Nishikawa, Hiroki
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-15
- Volume
- 22
- Issue
- 4
- Pages
- 1917
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7919019
- OpenAlex
- W3129491662
- Cited by
- 56
- References
- 100
- Citations by year
- 2026: 10 · 2025: 4 · 2024: 12 · 2023: 14 · 2022: 9 · 2021: 7
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- sarcopenic obesity, liver cirrhosis, sarcopenia, obesity, protein-energy malnutrition, chronic liver disease, non-alcoholic fatty liver disease, muscle mass loss, inflammatory cytokines, oxidative stress, insulin resistance, endocrine disorders, physical inactivity, pathogenesis
- MeSH terms
- Adipose Tissue, Exercise Therapy, Fasting, Humans, Insulin Resistance, Liver Cirrhosis, Obesity, Protein-Energy Malnutrition, Cytokines, Sarcopenia, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
